US20030185882A1 - Pharmaceutical compositions containing oxybutynin - Google Patents

Pharmaceutical compositions containing oxybutynin Download PDF

Info

Publication number
US20030185882A1
US20030185882A1 US09/992,488 US99248801A US2003185882A1 US 20030185882 A1 US20030185882 A1 US 20030185882A1 US 99248801 A US99248801 A US 99248801A US 2003185882 A1 US2003185882 A1 US 2003185882A1
Authority
US
United States
Prior art keywords
drug
oxybutynin
osmotic device
dosage form
order
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/992,488
Other languages
English (en)
Inventor
Juan Vergez
Marcelo Ricci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osmotica Kereskedelmi es Szolgaltato KFT
Original Assignee
Osmotica Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25538393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20030185882(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Osmotica Corp filed Critical Osmotica Corp
Priority to US09/992,488 priority Critical patent/US20030185882A1/en
Assigned to OSMOTICA CORP. reassignment OSMOTICA CORP. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RICCI, MARCELO A., VERGEZ, JUAN A.
Priority to ARP020104231A priority patent/AR037256A1/es
Priority to PCT/CR2002/000007 priority patent/WO2003039436A2/es
Priority to PCT/CR2002/000006 priority patent/WO2003039519A2/es
Priority to UY27532A priority patent/UY27532A1/es
Priority to AU2002363360A priority patent/AU2002363360A1/en
Priority to ARP020104230A priority patent/AR037255A1/es
Priority to AU2002363361A priority patent/AU2002363361A1/en
Priority to BR0213948-0A priority patent/BR0213948A/pt
Priority to EP02798241A priority patent/EP1461018A2/en
Priority to UY27533A priority patent/UY27533A1/es
Publication of US20030185882A1 publication Critical patent/US20030185882A1/en
Priority to US11/321,736 priority patent/US8241667B2/en
Priority to US11/355,315 priority patent/US8329217B2/en
Assigned to OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT reassignment OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: OSMOTICA CORP.
Priority to US13/625,658 priority patent/US8591947B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
US09/992,488 2001-11-06 2001-11-06 Pharmaceutical compositions containing oxybutynin Abandoned US20030185882A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
US09/992,488 US20030185882A1 (en) 2001-11-06 2001-11-06 Pharmaceutical compositions containing oxybutynin
EP02798241A EP1461018A2 (en) 2001-11-06 2002-11-06 Dual controlled release dosage form
UY27533A UY27533A1 (es) 2001-11-06 2002-11-06 Composiciones farmacéuticas que contienen oxibutinina
AU2002363361A AU2002363361A1 (en) 2001-11-06 2002-11-06 Pharmaceutical compositions containing oxybutynin
BR0213948-0A BR0213948A (pt) 2001-11-06 2002-11-06 Forma de dosagem de liberação controlada dual
PCT/CR2002/000006 WO2003039519A2 (es) 2001-11-06 2002-11-06 Forma de dosificación de liberación controlada dual
UY27532A UY27532A1 (es) 2001-11-06 2002-11-06 Forma de dosificación de liberación controlada dual.
AU2002363360A AU2002363360A1 (en) 2001-11-06 2002-11-06 Dual controlled release dosage form
ARP020104230A AR037255A1 (es) 2001-11-06 2002-11-06 Composiciones farmaceuticas que contienen oxibutinina
ARP020104231A AR037256A1 (es) 2001-11-06 2002-11-06 Forma de dosificacion de liberacion controlada dual
PCT/CR2002/000007 WO2003039436A2 (es) 2001-11-06 2002-11-06 Composiciones farmaceuticas que contienen oxibutinina
US11/321,736 US8241667B2 (en) 2001-11-06 2005-12-29 Dual controlled release osmotic device
US11/355,315 US8329217B2 (en) 2001-11-06 2006-02-15 Dual controlled release dosage form
US13/625,658 US8591947B2 (en) 2001-11-06 2012-09-24 Dual controlled release dosage form

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/992,488 US20030185882A1 (en) 2001-11-06 2001-11-06 Pharmaceutical compositions containing oxybutynin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/321,736 Division US8241667B2 (en) 2001-11-06 2005-12-29 Dual controlled release osmotic device

Publications (1)

Publication Number Publication Date
US20030185882A1 true US20030185882A1 (en) 2003-10-02

Family

ID=25538393

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/992,488 Abandoned US20030185882A1 (en) 2001-11-06 2001-11-06 Pharmaceutical compositions containing oxybutynin
US11/321,736 Active 2026-05-16 US8241667B2 (en) 2001-11-06 2005-12-29 Dual controlled release osmotic device

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/321,736 Active 2026-05-16 US8241667B2 (en) 2001-11-06 2005-12-29 Dual controlled release osmotic device

Country Status (7)

Country Link
US (2) US20030185882A1 (es)
EP (1) EP1461018A2 (es)
AR (2) AR037256A1 (es)
AU (2) AU2002363361A1 (es)
BR (1) BR0213948A (es)
UY (2) UY27533A1 (es)
WO (2) WO2003039519A2 (es)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010009995A1 (en) * 1998-03-26 2001-07-26 Gupta Suneel K. Oxybutynin therapy
US20030175346A1 (en) * 2002-02-01 2003-09-18 Anne Billotte Osmotic delivery system
US20040091529A1 (en) * 2002-06-26 2004-05-13 David Edgren Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US20040115262A1 (en) * 2002-07-29 2004-06-17 Frank Jao Formulations and dosage forms for controlled delivery of topiramate
US20050058707A1 (en) * 2003-08-06 2005-03-17 Iran Reyes Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
US20050175690A1 (en) * 2003-12-29 2005-08-11 David Edgren Novel drug compositions and dosage forms
US20050175697A1 (en) * 2003-12-29 2005-08-11 David Edgren Novel drug compositions and dosage forms of topiramate
US20050191351A1 (en) * 2003-11-04 2005-09-01 Shire Laboratories, Inc. Once daily dosage forms of trospium
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
US20050271691A1 (en) * 2003-02-21 2005-12-08 Cardio Combos Llc Prepackaged aqueous pharmaceutical formulations
EP1629834A1 (en) * 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
US20060141050A1 (en) * 2002-03-26 2006-06-29 Lerner Itzhak E Drug microparticles
US20090022797A1 (en) * 2007-07-20 2009-01-22 Mylan Pharmaceuticals Inc Stabilized tolterodine tartrate formulations
WO2009014533A1 (en) * 2007-07-20 2009-01-29 Mylan Pharmaceuticals , Inc Drug formulations having inert sealed cores
WO2009052353A2 (en) * 2007-10-17 2009-04-23 Dr. Reddy's Laboratories Ltd. Trospium pharmaceutical formulations
CN102048706A (zh) * 2011-01-12 2011-05-11 山东创新药物研发有限公司 一种氢溴酸达非那新缓释片及制备方法
CN103127023A (zh) * 2013-03-01 2013-06-05 南京正宽医药科技有限公司 一种盐酸度洛西汀肠溶片及其制备方法
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
US8932628B2 (en) 2005-06-27 2015-01-13 Valeant International Bermuda Modified release formulations of a bupropion salt
US9393192B2 (en) 2002-07-29 2016-07-19 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20200206130A1 (en) * 2017-05-23 2020-07-02 Catalent UK Supply Chain Limited Implantable drug delivery device
US20210145753A1 (en) * 2012-05-14 2021-05-20 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
JP2007522249A (ja) * 2004-02-13 2007-08-09 ニューロモレキュラー・インコーポレイテッド 精神医学的状態の処置のための、ｎｍｄａレセプターアンタゴニストと、抗うつ薬であるｍａｏインヒビターまたはｇａｄｐｈインヒビターとの併用
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
BRPI0518506A2 (pt) 2005-01-27 2008-12-02 Alembic Ltd tablete e formulaÇço de liberaÇço prolongada de levetiracetam
EP2032124A1 (en) * 2006-06-27 2009-03-11 Biovail Laboratories International Srl Multiparticulate osmotic delivery system
US20080014264A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
WO2010089259A2 (en) 2009-02-04 2010-08-12 Woerwag R&D Gmbh Sustained release composition containing quetiapine
WO2011161504A1 (en) * 2010-06-23 2011-12-29 Micro Labs Limited Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof
CN103156804A (zh) * 2011-12-13 2013-06-19 重庆医药工业研究院有限责任公司 一种奥昔布宁透皮凝胶及其制备方法
BR112020015316A2 (pt) * 2018-01-30 2020-12-08 Apnimed, Inc. (Delaware) Métodos e composições para o tratamento da apneia do sono

Citations (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4309996A (en) * 1980-04-28 1982-01-12 Alza Corporation System with microporous releasing diffusor
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4455143A (en) * 1982-03-22 1984-06-19 Alza Corporation Osmotic device for dispensing two different medications
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
US4627971A (en) * 1985-04-22 1986-12-09 Alza Corporation Osmotic device with self-sealing passageway
US4662880A (en) * 1986-03-14 1987-05-05 Alza Corporation Pseudoephedrine, brompheniramine therapy
US4681583A (en) * 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4765957A (en) * 1986-12-29 1988-08-23 Carondelet Foundry Company Alloy resistant to seawater and other corrosive fluids
US4814181A (en) * 1987-09-03 1989-03-21 Alza Corporation Dosage form comprising fast agent delivery followed by slow agent delivery
US4863456A (en) * 1986-04-30 1989-09-05 Alza Corporation Dosage form with improved delivery capability
US4867969A (en) * 1986-02-07 1989-09-19 Alza Corporation Hydrogel formulation for administering non-steroidal drugs
US4909474A (en) * 1987-05-15 1990-03-20 Dyckerhoff & Widmann Aktiengessellschaft Apparatus for locating operational surfaces on a track for electromagnetically levitated vehicles
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US4960416A (en) * 1986-04-30 1990-10-02 Alza Corporation Dosage form with improved delivery capability
US4971790A (en) * 1986-02-07 1990-11-20 Alza Corporation Dosage form for lessening irritation of mocusa
US5006348A (en) * 1990-05-04 1991-04-09 Kraft General Foods, Inc. Method for manufacture of swiss cheese
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5190785A (en) * 1990-06-13 1993-03-02 Manfred Oelsner Method for the manufacture of pectinous and sacchariferous preparations, such as jam, marmalade or the like
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
US5543155A (en) * 1993-12-09 1996-08-06 Egis Gyogyszergyar Rt. Diffusion-osmotic controlled drug-release pharmaceutical composition and process for preparing same
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5866164A (en) * 1996-03-12 1999-02-02 Alza Corporation Composition and dosage form comprising opioid antagonist
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6106864A (en) * 1995-09-15 2000-08-22 Pfizer Inc. Pharmaceutical formulations containing darifenacin
US20020010216A1 (en) * 2000-02-24 2002-01-24 Karen Rogosky New drug combinations
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552880A (en) * 1983-02-15 1985-11-12 Merrell Dow Pharmaceuticals Inc. Aroylimidazolones
US4661583A (en) * 1985-06-24 1987-04-28 Ashland Oil, Inc. Reaction of bicyclic amide acetal with imide
WO1988001170A1 (en) * 1986-08-20 1988-02-25 Teikoku Seiyaku Co., Ltd. Steroidal drug-containing preparation for external use
US5236689A (en) * 1987-06-25 1993-08-17 Alza Corporation Multi-unit delivery system
US4996061A (en) * 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
US4904474A (en) 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
US5976571A (en) * 1991-01-31 1999-11-02 Port Systems, L.L.C. Method for making a multi-stage drug delivery system
US5190765A (en) * 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
JP2646170B2 (ja) 1992-06-24 1997-08-25 日本ヘキスト・マリオン・ルセル株式会社 徐放性塩酸オキシブチニン製剤
US5643155A (en) * 1993-11-02 1997-07-01 Kallassy; Charles Aquatic exercise device
WO1996012477A1 (en) 1994-10-21 1996-05-02 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
WO1997016814A1 (en) 1995-11-03 1997-05-09 Sierra Semiconductor Corporation Yuv video backend filter
JP2665658B2 (ja) 1995-12-18 1997-10-22 住友特殊金属株式会社 希土類・鉄・コバルト・ボロン系正方晶化合物
ES2141044B1 (es) * 1997-02-26 2001-02-01 Alza Corp Terapia con oxibutinina.
US5866184A (en) * 1997-03-12 1999-02-02 World Class Packaging Systems, Inc. Method of packaging a food product in a ventable package
DE69818607T2 (de) * 1997-05-30 2004-07-29 Osmotica Corp. Mehrlagige osmosevorrichtung
SI1039882T1 (sl) 1998-08-27 2011-01-31 Pfizer Health Ab Terapevtska formulacija za dajanje tolterodina s kontroliranim sproščanjem
WO2000019997A1 (en) 1998-10-07 2000-04-13 Alza Corporation Controlled release dosage from comprising oxybutynin
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form

Patent Citations (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4309996A (en) * 1980-04-28 1982-01-12 Alza Corporation System with microporous releasing diffusor
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4455143A (en) * 1982-03-22 1984-06-19 Alza Corporation Osmotic device for dispensing two different medications
US4681583A (en) * 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
US4627971A (en) * 1985-04-22 1986-12-09 Alza Corporation Osmotic device with self-sealing passageway
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4867969A (en) * 1986-02-07 1989-09-19 Alza Corporation Hydrogel formulation for administering non-steroidal drugs
US4971790A (en) * 1986-02-07 1990-11-20 Alza Corporation Dosage form for lessening irritation of mocusa
US4662880A (en) * 1986-03-14 1987-05-05 Alza Corporation Pseudoephedrine, brompheniramine therapy
US4863456A (en) * 1986-04-30 1989-09-05 Alza Corporation Dosage form with improved delivery capability
US4960416A (en) * 1986-04-30 1990-10-02 Alza Corporation Dosage form with improved delivery capability
US4765957A (en) * 1986-12-29 1988-08-23 Carondelet Foundry Company Alloy resistant to seawater and other corrosive fluids
US4909474A (en) * 1987-05-15 1990-03-20 Dyckerhoff & Widmann Aktiengessellschaft Apparatus for locating operational surfaces on a track for electromagnetically levitated vehicles
US4814181A (en) * 1987-09-03 1989-03-21 Alza Corporation Dosage form comprising fast agent delivery followed by slow agent delivery
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5006348A (en) * 1990-05-04 1991-04-09 Kraft General Foods, Inc. Method for manufacture of swiss cheese
US5190785A (en) * 1990-06-13 1993-03-02 Manfred Oelsner Method for the manufacture of pectinous and sacchariferous preparations, such as jam, marmalade or the like
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5543155A (en) * 1993-12-09 1996-08-06 Egis Gyogyszergyar Rt. Diffusion-osmotic controlled drug-release pharmaceutical composition and process for preparing same
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5840754A (en) * 1995-05-22 1998-11-24 Alza Corporation Dosage form comprising oxybutynin
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6106864A (en) * 1995-09-15 2000-08-22 Pfizer Inc. Pharmaceutical formulations containing darifenacin
US5866164A (en) * 1996-03-12 1999-02-02 Alza Corporation Composition and dosage form comprising opioid antagonist
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US20020010216A1 (en) * 2000-02-24 2002-01-24 Karen Rogosky New drug combinations

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010009995A1 (en) * 1998-03-26 2001-07-26 Gupta Suneel K. Oxybutynin therapy
US20030175346A1 (en) * 2002-02-01 2003-09-18 Anne Billotte Osmotic delivery system
US20060141050A1 (en) * 2002-03-26 2006-06-29 Lerner Itzhak E Drug microparticles
US20040091529A1 (en) * 2002-06-26 2004-05-13 David Edgren Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US20040115262A1 (en) * 2002-07-29 2004-06-17 Frank Jao Formulations and dosage forms for controlled delivery of topiramate
US9393192B2 (en) 2002-07-29 2016-07-19 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20050271691A1 (en) * 2003-02-21 2005-12-08 Cardio Combos Llc Prepackaged aqueous pharmaceutical formulations
US20050058707A1 (en) * 2003-08-06 2005-03-17 Iran Reyes Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
US7781449B2 (en) 2003-11-04 2010-08-24 Supernus Pharmaceuticals, Inc. Trospium chloride treatment method
US20100221355A1 (en) * 2003-11-04 2010-09-02 Supernus Pharmaceuticals, Inc. Pharmaceutical composition for once-a-day oral administration of trospium chloride
US20050191351A1 (en) * 2003-11-04 2005-09-01 Shire Laboratories, Inc. Once daily dosage forms of trospium
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
US20100221354A1 (en) * 2003-11-04 2010-09-02 Supernus Pharmaceuticals, Inc. Pharmaceutical composition for once-a-day oral administration of trospium chloride
US20100222375A1 (en) * 2003-11-04 2010-09-02 Supernus Pharmaceuticals, Inc. Pharmaceutical Composition Comprising Trospium Chloride for Once-A-Day Administration
JP2007510656A (ja) * 2003-11-04 2007-04-26 スパーナス ファーマシューティカルズ インコーポレイテッド トロスピウムの１日１回剤形
US7410978B2 (en) * 2003-11-04 2008-08-12 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
US20080207661A1 (en) * 2003-11-04 2008-08-28 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
US20080207662A1 (en) * 2003-11-04 2008-08-28 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
US20080207663A1 (en) * 2003-11-04 2008-08-28 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
US20100221353A1 (en) * 2003-11-04 2010-09-02 Supernus Pharmaceuticals, Inc. Pharmaceutical Composition For Once-A-Day Administration of Trospium Chloride
US20100221352A1 (en) * 2003-11-04 2010-09-02 Supernus Pharmaceuticals, Inc. Pharmaceutical composition for the once-a-day oral administration of trospium chloride
US7781448B2 (en) 2003-11-04 2010-08-24 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
US7763635B2 (en) 2003-11-04 2010-07-27 Supermus Pharmaceuticals, Inc. Once daily dosage forms of trospium
US7759359B2 (en) 2003-11-04 2010-07-20 Supernus Pharmaceuticals, Inc. Method of treating bladder dysfunction with once-a-day trospium salt formulation
US20050175697A1 (en) * 2003-12-29 2005-08-11 David Edgren Novel drug compositions and dosage forms of topiramate
US20050175690A1 (en) * 2003-12-29 2005-08-11 David Edgren Novel drug compositions and dosage forms
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
EP1964553A1 (en) * 2004-08-27 2008-09-03 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
WO2006021425A1 (en) * 2004-08-27 2006-03-02 Krka Sustained release pharmaceutical composition of tolterodine
EP1629834A1 (en) * 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
US9504640B2 (en) 2005-06-27 2016-11-29 Valeant Pharmaceuticals Luxembourg S.Á.R.L. Modified release formulations of a bupropion salt
US8932628B2 (en) 2005-06-27 2015-01-13 Valeant International Bermuda Modified release formulations of a bupropion salt
US20090022797A1 (en) * 2007-07-20 2009-01-22 Mylan Pharmaceuticals Inc Stabilized tolterodine tartrate formulations
WO2009014533A1 (en) * 2007-07-20 2009-01-29 Mylan Pharmaceuticals , Inc Drug formulations having inert sealed cores
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8778397B2 (en) 2007-07-20 2014-07-15 Mylan, Inc. Stabilized tolterodine tartrate formulations
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
WO2009052353A2 (en) * 2007-10-17 2009-04-23 Dr. Reddy's Laboratories Ltd. Trospium pharmaceutical formulations
WO2009052353A3 (en) * 2007-10-17 2009-08-06 Reddys Lab Ltd Dr Trospium pharmaceutical formulations
CN102048706A (zh) * 2011-01-12 2011-05-11 山东创新药物研发有限公司 一种氢溴酸达非那新缓释片及制备方法
US20210145753A1 (en) * 2012-05-14 2021-05-20 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
CN103127023A (zh) * 2013-03-01 2013-06-05 南京正宽医药科技有限公司 一种盐酸度洛西汀肠溶片及其制备方法
US20200206130A1 (en) * 2017-05-23 2020-07-02 Catalent UK Supply Chain Limited Implantable drug delivery device

Also Published As

Publication number Publication date
UY27532A1 (es) 2003-05-30
AR037255A1 (es) 2004-11-03
US20060177510A1 (en) 2006-08-10
WO2003039436A2 (es) 2003-05-15
AU2002363361A1 (en) 2003-05-19
UY27533A1 (es) 2003-05-30
EP1461018A2 (en) 2004-09-29
WO2003039436A3 (es) 2004-02-26
WO2003039519A2 (es) 2003-05-15
BR0213948A (pt) 2004-08-31
AR037256A1 (es) 2004-11-03
US8241667B2 (en) 2012-08-14
AU2002363360A1 (en) 2003-05-19
WO2003039519A3 (es) 2004-03-25

Similar Documents

Publication Publication Date Title
US8241667B2 (en) Dual controlled release osmotic device
US8591947B2 (en) Dual controlled release dosage form
US6605302B2 (en) Drug delivery device containing oseltamivir and an H1 antagonist
EP1246612B1 (en) Osmotic device containing pseudoephedrine and fexofenadine
US7008641B2 (en) Osmotic device containing venlafaxine and an anti-psychotic agent
US9833412B2 (en) Triple combination release multi-layered tablet
US6248359B1 (en) Multi-tablet oxybutynin system for treating incontinence
US20040204413A1 (en) Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant
US6599532B2 (en) Osmotic device containing alprazolam and an antipsychotic agent
JP5325421B2 (ja) アマンタジンおよび浸透塩を含有する浸透デバイス
US10471031B2 (en) Controlled release dosage form
US6521255B2 (en) Osmotic device containing ranitidine and a prokinetic agent
EP1714641B1 (en) Osmotic device containing a venlafaxine salt and a salt having a common ion
US7147870B2 (en) Osmotic device containing pseudoephedrine and an H1 antagonist
CA2614647C (en) Osmotic device containing venlafaxine and an anti-psychotic agent
MX2008008487A (es) Comprimido multicapa con combinacion de triple liberacion

Legal Events

Date Code Title Description
AS Assignment

Owner name: OSMOTICA CORP., VIRGIN ISLANDS, BRITISH

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VERGEZ, JUAN A.;RICCI, MARCELO A.;REEL/FRAME:012573/0364

Effective date: 20011214

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT, HUNGARY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:OSMOTICA CORP.;REEL/FRAME:025695/0485

Effective date: 20100119